Drug Profile
FDY 5301
Alternative Names: FDY-5301Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Faraday Pharmaceuticals
- Class Cardiovascular therapies; Reducing agents
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myocardial infarction
- Phase II Musculoskeletal disorders; Sarcopenia
- No development reported Reperfusion injury
Most Recent Events
- 04 Jan 2024 European Patent Office notice allows for expansion of FDY 5301 patent protection into the EU
- 10 May 2022 Faraday Pharmaceuticals initiates enrolment in the phase III IOCYTE AMI-3 trial for Myocardial infarction in USA (NCT04837001)
- 02 May 2022 Phase-III clinical trials in Myocardial infarction in Canada, Israel (IV) (NCT04837001)